446 related articles for article (PubMed ID: 20098683)
1. The synthesis of truncated polypeptides for immune surveillance and viral evasion.
Cardinaud S; Starck SR; Chandra P; Shastri N
PLoS One; 2010 Jan; 5(1):e8692. PubMed ID: 20098683
[TBL] [Abstract][Full Text] [Related]
2. Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation.
Apcher S; Daskalogianni C; Manoury B; Fåhraeus R
PLoS Pathog; 2010 Oct; 6(10):e1001151. PubMed ID: 20976201
[TBL] [Abstract][Full Text] [Related]
3. Messenger RNA sequence rather than protein sequence determines the level of self-synthesis and antigen presentation of the EBV-encoded antigen, EBNA1.
Tellam JT; Lekieffre L; Zhong J; Lynn DJ; Khanna R
PLoS Pathog; 2012 Dec; 8(12):e1003112. PubMed ID: 23300450
[TBL] [Abstract][Full Text] [Related]
4. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules?
Yewdell JW; Antón LC; Bennink JR
J Immunol; 1996 Sep; 157(5):1823-6. PubMed ID: 8757297
[TBL] [Abstract][Full Text] [Related]
5. A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus.
Voisset C; Daskalogianni C; Contesse MA; Mazars A; Arbach H; Le Cann M; Soubigou F; Apcher S; Fåhraeus R; Blondel M
Dis Model Mech; 2014 Apr; 7(4):435-44. PubMed ID: 24558096
[TBL] [Abstract][Full Text] [Related]
6. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.
Voo KS; Fu T; Wang HY; Tellam J; Heslop HE; Brenner MK; Rooney CM; Wang RF
J Exp Med; 2004 Feb; 199(4):459-70. PubMed ID: 14769850
[TBL] [Abstract][Full Text] [Related]
7. Novel cationic bis(acylhydrazones) as modulators of Epstein-Barr virus immune evasion acting through disruption of interaction between nucleolin and G-quadruplexes of EBNA1 mRNA.
Reznichenko O; Quillévéré A; Martins RP; Loaëc N; Kang H; Lista MJ; Beauvineau C; González-García J; Guillot R; Voisset C; Daskalogianni C; Fåhraeus R; Teulade-Fichou MP; Blondel M; Granzhan A
Eur J Med Chem; 2019 Sep; 178():13-29. PubMed ID: 31173968
[TBL] [Abstract][Full Text] [Related]
8. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.
Yin Y; Manoury B; Fåhraeus R
Science; 2003 Sep; 301(5638):1371-4. PubMed ID: 12958359
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
[TBL] [Abstract][Full Text] [Related]
10. Mature proteins derived from Epstein-Barr virus fail to feed into the MHC class I antigenic pool.
Fiebiger BM; Moosmann A; Behrends U; Mautner J
Eur J Immunol; 2012 Dec; 42(12):3167-73. PubMed ID: 22944914
[TBL] [Abstract][Full Text] [Related]
11. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.
Khanna R; Burrows SR; Steigerwald-Mullen PM; Thomson SA; Kurilla MG; Moss DJ
Virology; 1995 Dec; 214(2):633-7. PubMed ID: 8553567
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
Albanese M; Tagawa T; Bouvet M; Maliqi L; Lutter D; Hoser J; Hastreiter M; Hayes M; Sugden B; Martin L; Moosmann A; Hammerschmidt W
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6467-E6475. PubMed ID: 27698133
[TBL] [Abstract][Full Text] [Related]
13. The DRiP hypothesis decennial: support, controversy, refinement and extension.
Yewdell JW; Nicchitta CV
Trends Immunol; 2006 Aug; 27(8):368-73. PubMed ID: 16815756
[TBL] [Abstract][Full Text] [Related]
14. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.
Khanna R; Burrows SR; Steigerwald-Mullen PM; Moss DJ; Kurilla MG; Cooper L
Int Immunol; 1997 Oct; 9(10):1537-43. PubMed ID: 9352359
[TBL] [Abstract][Full Text] [Related]
15. Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA.
Lista MJ; Martins RP; Billant O; Contesse MA; Findakly S; Pochard P; Daskalogianni C; Beauvineau C; Guetta C; Jamin C; Teulade-Fichou MP; Fåhraeus R; Voisset C; Blondel M
Nat Commun; 2017 Jul; 8():16043. PubMed ID: 28685753
[TBL] [Abstract][Full Text] [Related]
16. DRiPs solidify: progress in understanding endogenous MHC class I antigen processing.
Yewdell JW
Trends Immunol; 2011 Nov; 32(11):548-58. PubMed ID: 21962745
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
18. Immune evasion proteins of murine cytomegalovirus preferentially affect cell surface display of recently generated peptide presentation complexes.
Lemmermann NA; Gergely K; Böhm V; Deegen P; Däubner T; Reddehase MJ
J Virol; 2010 Feb; 84(3):1221-36. PubMed ID: 19906905
[TBL] [Abstract][Full Text] [Related]
19. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.
Tellam J; Connolly G; Green KJ; Miles JJ; Moss DJ; Burrows SR; Khanna R
J Exp Med; 2004 May; 199(10):1421-31. PubMed ID: 15148340
[TBL] [Abstract][Full Text] [Related]
20. RNA polymerase II inhibitors dissociate antigenic peptide generation from normal viral protein synthesis: a role for nuclear translation in defective ribosomal product synthesis?
Dolan BP; Knowlton JJ; David A; Bennink JR; Yewdell JW
J Immunol; 2010 Dec; 185(11):6728-33. PubMed ID: 21048111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
